Contribution of microbiome to inhibitor development in haemophilia A
Research type
Research Study
Full title
Does the composition of the microbiome correlate with the development of FVIII-neutralising antibodies in haemophila A patients?
IRAS ID
271423
Contact name
Carmen Coxon
Contact email
Sponsor organisation
National Institute Biological Standards and Control
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
Development of FVIII-neutralising antibodies ('inhibitors') in haemophilia A (HA) patients is a serious complication of treatment. The microbiome influences many aspects of pathophysiology, including the immune system. Recent work (communicated at the ISTH 2019 meeting) revealed that loss of the microbiome from haemophila A mice (a experimental model for the human disease) resulted in an increase in 'inhibitor titre' (strength of the response). We are interested to know if this also affects inhibitor development in the human disease. To investigate this we will collect stool samples from severe HA patients at/before first exposure to FVIII and after 50 doses (by which point inhibitors have usually developed). We will compare the microbiome of patients that develop inhibitors to those that do not to determine if there is a correlation between the composition of the patient's microbiome and inhibitor development.
REC name
London - Central Research Ethics Committee
REC reference
20/LO/0406
Date of REC Opinion
23 Mar 2020
REC opinion
Favourable Opinion